I agree to all those posters who said that there is no further news to wait for after the full data from the HSV-2 Phase 1 study are released this quarter.........
.......oh wait..... I forgot these items below. How silly of me to forget even though they were previous published a couple of times yesterday in this forum.
- Extending the use of CardioCel® for an expanded range of indications in cardiovascular surgery;
- Expanding regenerative tissue portfolio and explore the use of ADAPT® prepared tissue for additional surgical applications that have the potential to increase revenue in the future;
- Initial Asian market approval for CardioCel®;
- Initiation of HSV-2 Phase II; and
- Initiation of HPV Phase I.
- Forums
- ASX - By Stock
- AVR
- News: Admedus revenue up 7.09% for FY2014
News: Admedus revenue up 7.09% for FY2014, page-23
-
- There are more pages in this discussion • 19 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add AVR (ASX) to my watchlist
(20min delay)
|
|||||
Last
$17.95 |
Change
-0.050(0.28%) |
Mkt cap ! $341.1M |
Open | High | Low | Value | Volume |
$18.00 | $18.00 | $17.75 | $63.92K | 3.573K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 124 | $17.93 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$18.00 | 354 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 691 | 17.900 |
1 | 1 | 17.800 |
1 | 26 | 17.740 |
1 | 443 | 17.700 |
1 | 26 | 17.650 |
Price($) | Vol. | No. |
---|---|---|
17.910 | 43 | 3 |
17.930 | 31 | 2 |
17.950 | 289 | 3 |
18.000 | 300 | 1 |
18.250 | 100 | 1 |
Last trade - 15.35pm 15/07/2024 (20 minute delay) ? |
Featured News
AVR (ASX) Chart |
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, MD & CEO / Non-Executive Director
James Graham / Dr Alan Dunton
MD & CEO / Non-Executive Director
SPONSORED BY The Market Online